中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
10期
1364-1366
,共3页
冠心病%奥美拉唑%法莫替丁%抗血小板%血小板聚集阈值%血小板最大聚集率
冠心病%奧美拉唑%法莫替丁%抗血小闆%血小闆聚集閾值%血小闆最大聚集率
관심병%오미랍서%법막체정%항혈소판%혈소판취집역치%혈소판최대취집솔
Coronary artery disease%Omeprazole%Famotidine%Antiplatelet%Platelet aggregation threshold index%Platelet aggregation rate
目的 研究奥美拉唑和法莫替丁对冠心病患者氯吡格雷和阿司匹林抗血小板治疗的影响.方法 选择2011年6月至2013年1月在商丘市第一人民医院接受双重抗血小板治疗的186例冠心病患者.根据治疗方法不同分为对照组(66例)、奥美拉唑组(88例)和法莫替丁组(32例).其中对照组患者使用阿司匹林肠溶片(0.1 g/d)+氯吡格雷片(75 mg/d)；奥美拉唑组患者使用阿司匹林肠溶片(0.1 g/d)+氯吡格雷片(75 mg/d)+奥美拉唑(40 mg/d,静脉滴注)；法莫替丁组患者使用阿司匹林肠溶片(0.1 g/d)+氯吡格雷片(75 mg/d)+法莫替丁(20 mg,2次/d,口服).检测指标:血小板聚集阈值,二磷酸腺苷(ADP)和胶原蛋白诱导的血小板聚集率.结果 对照组ADP-血小板聚集阈值为(3.5±1.0)μmol/L,法莫替丁组为(3.8±0.5) μmol/L,奥美拉唑组为(3.4±0.9)μmol/L,各组比较差异无统计学意义(P＞0.05).对照组胶原蛋白-血小板聚集阈值为(1.93 ±0.25) mg/L,法莫替丁组为(1.99 ±O.03) mg/L,奥美拉唑组为(1.95±0.16)mg/L,各组比较差异无统计学意义(P＞0.05).法莫替丁组和对照组在胶原蛋白0.5 mg/L诱导的聚集率差异有统计学意义[(7.1±2.3)％比(9.4±6.6％),P＜0.05],但法莫替丁组和对照组在胶原蛋白诱导的最大聚集率差异无统计学意义(P＜0.05).血小板聚集率在对照组和奥美拉唑组间差异无统计学意义(P＞0.05).结论 冠心病患者在双重抗血小板治疗期间,联用奥美拉唑或法莫替丁并不影响氯吡格雷和阿司匹林的抗血小板作用.
目的 研究奧美拉唑和法莫替丁對冠心病患者氯吡格雷和阿司匹林抗血小闆治療的影響.方法 選擇2011年6月至2013年1月在商丘市第一人民醫院接受雙重抗血小闆治療的186例冠心病患者.根據治療方法不同分為對照組(66例)、奧美拉唑組(88例)和法莫替丁組(32例).其中對照組患者使用阿司匹林腸溶片(0.1 g/d)+氯吡格雷片(75 mg/d)；奧美拉唑組患者使用阿司匹林腸溶片(0.1 g/d)+氯吡格雷片(75 mg/d)+奧美拉唑(40 mg/d,靜脈滴註)；法莫替丁組患者使用阿司匹林腸溶片(0.1 g/d)+氯吡格雷片(75 mg/d)+法莫替丁(20 mg,2次/d,口服).檢測指標:血小闆聚集閾值,二燐痠腺苷(ADP)和膠原蛋白誘導的血小闆聚集率.結果 對照組ADP-血小闆聚集閾值為(3.5±1.0)μmol/L,法莫替丁組為(3.8±0.5) μmol/L,奧美拉唑組為(3.4±0.9)μmol/L,各組比較差異無統計學意義(P＞0.05).對照組膠原蛋白-血小闆聚集閾值為(1.93 ±0.25) mg/L,法莫替丁組為(1.99 ±O.03) mg/L,奧美拉唑組為(1.95±0.16)mg/L,各組比較差異無統計學意義(P＞0.05).法莫替丁組和對照組在膠原蛋白0.5 mg/L誘導的聚集率差異有統計學意義[(7.1±2.3)％比(9.4±6.6％),P＜0.05],但法莫替丁組和對照組在膠原蛋白誘導的最大聚集率差異無統計學意義(P＜0.05).血小闆聚集率在對照組和奧美拉唑組間差異無統計學意義(P＞0.05).結論 冠心病患者在雙重抗血小闆治療期間,聯用奧美拉唑或法莫替丁併不影響氯吡格雷和阿司匹林的抗血小闆作用.
목적 연구오미랍서화법막체정대관심병환자록필격뢰화아사필림항혈소판치료적영향.방법 선택2011년6월지2013년1월재상구시제일인민의원접수쌍중항혈소판치료적186례관심병환자.근거치료방법불동분위대조조(66례)、오미랍서조(88례)화법막체정조(32례).기중대조조환자사용아사필림장용편(0.1 g/d)+록필격뢰편(75 mg/d)；오미랍서조환자사용아사필림장용편(0.1 g/d)+록필격뢰편(75 mg/d)+오미랍서(40 mg/d,정맥적주)；법막체정조환자사용아사필림장용편(0.1 g/d)+록필격뢰편(75 mg/d)+법막체정(20 mg,2차/d,구복).검측지표:혈소판취집역치,이린산선감(ADP)화효원단백유도적혈소판취집솔.결과 대조조ADP-혈소판취집역치위(3.5±1.0)μmol/L,법막체정조위(3.8±0.5) μmol/L,오미랍서조위(3.4±0.9)μmol/L,각조비교차이무통계학의의(P＞0.05).대조조효원단백-혈소판취집역치위(1.93 ±0.25) mg/L,법막체정조위(1.99 ±O.03) mg/L,오미랍서조위(1.95±0.16)mg/L,각조비교차이무통계학의의(P＞0.05).법막체정조화대조조재효원단백0.5 mg/L유도적취집솔차이유통계학의의[(7.1±2.3)％비(9.4±6.6％),P＜0.05],단법막체정조화대조조재효원단백유도적최대취집솔차이무통계학의의(P＜0.05).혈소판취집솔재대조조화오미랍서조간차이무통계학의의(P＞0.05).결론 관심병환자재쌍중항혈소판치료기간,련용오미랍서혹법막체정병불영향록필격뢰화아사필림적항혈소판작용.
Objective To investigate the influence of omeprazole or famotidine on the antiplatelet actions during dual-antiplatelet therapy(DAPT) in patients with coronary artery disease.Methods The patients underwent DAPT for coronary artery disease in our hospital from June 2011 to January 2013 were investigated.There were 223 patients with coronary artery disease.According to exclusion criteria,37 patients with DAPT were excluded.DAPT was conducted in 186 patients who underwent platelet aggregation function testing during the investigation period.66 patients were not given an antacid; concomitantly,the omeprazole (40 mg/d,ivgtt) was used in 88 patients ; 32 patients were given famotidine(20 mg,bid,po).100 mg/day of aspirin and 75 mg/day of clopidogrel were concomitantly used in all patients.Platelet aggregation rate and platelet aggregation threshold index (PATI) were measured.Results The ADP-PATI of control group,famotidine group and omeprazole group was (3.5 ± 1.0) μmol/L,(3.8 ±0.5)μmoL/L,(3.4 ± 0.9)μmoL/L,respectively.The collagen-PATI of control group,famotidine group,omeprazole group were (1.93 ± 0.25) mg/L,(1.99 ± 0.03) mg/L,(1.95 ± 0.16) mg/L,respectively.No statistically significant difference was observed regarding the ADP-PATI and collagen-PATI of respective groups compared to the control group(P ＞0.05).A signicicant difference was observed in platelet aggregation rate regarding the minimum concentration of collagen between the famotidine group and the control group [(7.1 ± 2.3) ％ vs (9.4 ±6.6) ％,P ＜ 0.05].There was also no statistically significant difference in the maximum platelet aggregation rate regarding the maximum concentration of ADP and collagen (P ＞ 0.05).Conclusion In patients with coronary artery disease,the concomitant use of omeprazole or famotidine does not affect antiplatelet action during DAPT.
